# UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD LUPIN LTD. AND LUPIN PHARMACEUTICALS INC., Petitioner v. HORIZON THERAPEUTICS, LLC, Patent Owner Case IPR2018-00459 Patent 9,561,197

## JOINT MOTION TO TERMINATE INTER PARTES REVIEW



## **TABLE OF CONTENTS**

I.	STATEMENT OF RELIEF REQUESTED		1
	STATEMENT OF FACTS		
III.	RELATED LITIGATION AND INTER PARTES REVIEWS		
IV.	7. ARGUMENT		
	A.	The Board Should Terminate this IPR in its Entirety	3
	B.	Written Settlement Agreement	5
V	CONCLUSION		4



## **TABLE OF AUTHORITIES**

## **Cases**

Apex Med. Corp. v. Resmed Ltd., IPR2013-00512, Paper 39 (P.T.A.B. Sept. 12, 2014)	4
Plaid Techs., Inc. v. Yodlee, Inc., IPR2016-00273, Paper 29 (P.T.A.B. Feb. 8, 2017)	4
Samsonite, LLC v. Otter Products, LLC, IPR2015-00507, Paper 13 (P.T.A.B. July 31, 2015)	4
Toyota Motor Corp. v. Blitzsafe Tex. LLC, IPR2016-00421, Paper 28 (P.T.A.B. Feb. 21, 2017)	4
Volution v. Versata Software, CBM2013-00018, Paper 52 (P.T.A.B. June 17, 2014)	4
<u>Statutes</u>	
35 U.S.C. § 317	4
35 U.S.C. § 317(a)	1, 2, 3
35 U.S.C. § 317(b)	5
Other Authorities	
Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756 (Aug. 14, 2012)	3, 5
Regulations	
37 C.F.R. § 42.107	1
37 C.F.R. § 42.72	3, 4
37 C.F.R. § 42.74	4
37 C F R 8 42 74(c)	1 5



### I. STATEMENT OF RELIEF REQUESTED

Pursuant to 35 U.S.C. § 317(a), Lupin Ltd. and Lupin Pharmaceuticals Inc. (collectively "Lupin" or "Petitioner") and Horizon Therapeutics, LLC ("Horizon" or "Patent Owner") jointly move that the Board terminate this *inter partes* review (IPR) proceeding, which is directed at U.S. Patent No. 9,561,197 ("the '197 patent"), in its entirety as a result of settlement between Petitioner and Patent Owner. *See* Ex. 2021 (Confidential).

The parties are concurrently filing a separate request that the settlement agreement (Ex. 2021) being filed herewith be treated as business confidential information and be kept separate from the files of the involved patent, pursuant to 37 C.F.R. § 42.74(c).

#### II. STATEMENT OF FACTS

Petitioner filed this IPR petition on January 12, 2018. On May 23, 2018, Patent Owner filed its Preliminary Response under 37 C.F.R. § 42.107. The Board has yet to issue a decision instituting *inter partes* review. Accordingly, no oral argument has been held and the Board has yet to issue a final decision in this matter.

On June 27, 2018, Petitioner and Patent Owner entered into a settlement agreement. *See* Ex. 2021 (Confidential). Under the terms of the settlement agreement, the parties agreed to jointly seek termination of IPR2018-00459, and



the parties agreed to dismiss related district court litigation, *Horizon Therapeutics*, *LLC v. Lupin Ltd. and Lupin Pharmaceuticals*, *Inc.*, Civil Action No. 2:17-cv-05900-KM-MAH (D.N.J., filed Aug. 8, 2017). Thus, this settlement agreement resolves all currently pending Patent Office and District Court proceedings between the parties involving the '197 patent.

### III. RELATED LITIGATION

The following currently pending district court litigation proceedings involve the '197 patent:

- (a) Horizon Therapeutics, LLC v. Lupin Ltd. and Lupin Pharmaceuticals, Inc., Civil Action No. 2:17-cv-05900-KM-MAH (D.N.J., filed Aug. 08, 2017). The Complaint asserts infringement of U.S. Patent No. 9,561,197.
- (b) *Horizon Therapeutics, LLC v. Par Pharmaceutical, Inc.*, Civil Action No. 2:17-cv-05901-KM-MAH (D.N.J. filed Aug. 08, 2017). The Complaint asserts infringement of U.S. Patent No. 9,561,197.

### IV. ARGUMENT

Section 317(a) provides: "An inter partes review instituted under this chapter shall be terminated with respect to any petitioner upon the joint request of the petitioner and the patent owner, unless the Office has decided the merits of the proceeding before the request for termination is filed." 35 U.S.C. § 317(a). It



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

